후성유전학(Epigenetics) 시장 : 2027년까지의 세계 예측

출판 : MarketsandMarkets(마켓츠앤마켓츠)출판년월 : 2022년07월

후성유전학(Epigenetics) 시장 : 제품 및 서비스 [효소 (DNA 변형 효소), 키트 및 시약 (항체), 소프트웨어, 서비스], 방법 (DNA 메틸화), 기술 (NGS, PCR 및 qPCR), 용도 (종양학, 면역학), 최종 사용자 – 2027년까지의 세계 예측
Epigenetics Market by Product & Service (Enzymes (DNA-modifying Enzymes), Kits & Reagents (Antibodies), Software, Service), Method (DNA Methylation), Technique (NGS, PCR & qPCR), Application (Oncology, Immunology), End User – Global Forecast to 2027

페이지수 239
도표수 309
구성 영문조사보고서
가격

리포트목차    주문/문의    납기/라이센스안내

Sample Request

The global epigenetics market is projected to reach USD 3.9 Billion by 2027 from USD 1.7 Billion in 2022, at a CAGR of 18.1% during the forecast period. Expanding non-oncology applications of epigenetics research is expected to open up new avenues of market expansion. Recent studies on epigenetics have been targeted toward periodontology, focusing on DNA methylation analysis. Increasing advancements in sequencing technology have opened new avenues for epigenetic studies enabling the assessment of specific genes and genome-wide analyses. With technological advancements, epigenetics research is anticipated to provide crucial information for developing dental medicine and expand the scope of ongoing large-scale research projects.
전 세계 후성유전학 시장은 예측 기간 동안 18.1%의 CAGR로 2022년 17억 달러에서 2027년 39억 달러에 이를 것으로 예상됩니다. 후성유전학 연구의 비종양학 적용 확대는 시장 확장의 새로운 길을 열 것으로 기대됩니다. 후성유전학에 대한 최근 연구는 DNA 메틸화 분석에 중점을 둔 치주학을 대상으로 하고 있습니다. 시퀀싱 기술의 발전이 증가하면서 특정 유전자의 평가와 전체 게놈 분석을 가능하게 하는 후성유전학적 연구를 위한 새로운 길을 열었습니다. 기술 발전에 따라 후성유전학 연구는 치과의학 발전에 중요한 정보를 제공하고 진행 중인 대규모 연구 프로젝트의 범위를 확대할 것으로 기대됩니다.

“The kits & reagents segment dominates the epigenetics market through the study period of 2020-2027.”

Based on product & service, the global epigenetics market is segmented into kits & reagents, enzymes, instruments and accessories, software, and service. The dominance of kits & reagents segment is attributed to affordable and convenient kits introduced by the market participants. This is expected to suffice the significant elevation in the number of epigenetics research activities conducted in the past few years. Additionally, market players are expanding their product offerings around epigenetics antibodies, which is further expected to supplement the segment’s dominance.

“The histone modifications segment will witness the highest growth in the epigenetics market during the forecast period.”

Based on method, the global epigenetics market is segmented into DNA methylation, histone modifications, and other methods. Histone modifications include different approaches such as, methylation, citrullination, ubiquitination, acetylation, and phosphorylation. Additionally, research professionals are focusing on understanding the potential of histone modifications in oncology which is expected to promote the segment growth through 2022 to 2027.

“North America dominated the epigenetics market in 2021.”
Geographically, the epigenetics market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. In 2021, North America accounted for the largest share of the epigenetics market. North America harbors majority of the key market players leading to maturity of epigenetics market in this region. Also, robust government support for academic & research activities offer opportunity for the key market players to introduce cutting-edge epigenetics products, further intensifying regional market competition.
The primary interviews conducted for this report can be categorized as follows:
• By Company Type – Tier 1: 37%, Tier 2: 23%, and Tier 3: 40%
• By Designation – C-level: 32%, D-level: 26%, and Others: 42%
• By Region – North America: 35%, Europe: 25%, Asia Pacific: 20%, Latin America: 12%, and the Middle East and Africa: 8%
List of Companies Profiled in the Report
• Thermo Fisher Scientific (US)
• Merck KGaA (Germany)
• Illumina, Inc. (US)
• PacBio (US)
• Abcam plc (UK)
• Active Motif, Inc. (US)
• Bio-Rad Laboratories (US)
• Promega Corporation (US)
• PerkinElmer (US)
• Qiagen (Germany)
• New England Biolabs (US)
• Zymo Research Corporation (US)
• Diagenode (Germany)
• F. Hoffmann-La Roche Ltd (Switzerland)
• EpiGentek Group Inc. (US)
• EpiCypher (US)
• Everon Life Sciences (India)
• Fios Genomics (UK)
• GenomeScan (Netherlands)
• Creative Biogene (US)

Research Coverage:
This report provides a detailed picture of the global epigenetics market. It aims at estimating the size and future growth potential of the market across different segments, such as product & service, method, technique, application, end user, and region. The report also analyzes factors (such as drivers, restraints, challenges, and opportunities) affecting the market growth. It evaluates the opportunities in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micromarkets with respect to their growth trends, prospects, and contributions to the total epigenetics market. The report forecasts the revenue of the market segments with respect to four major regions.

Reasons to Buy the Report:
The report provides insights on the following pointers:
• Market Penetration: Comprehensive information on epigenetics offered by the top 20 players in the epigenetics market. The report analyses the epigenetics market by product & service, method, technique, application, end user, and region.

• Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various epigenetics across key geographic regions.

• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the epigenetics market.

• Competitive Assessment: In-depth assessment of market ranking and strategies of the leading players in the epigenetics market.


목차

TABLE OF CONTENTS

1 INTRODUCTION (Page No. – 34)
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS AND EXCLUSIONS
1.3 MARKET SCOPE
FIGURE 1 EPIGENETICS MARKET
1.3.1 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY
1.5 LIMITATIONS
1.6 STAKEHOLDERS
1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY (Page No. – 38)
2.1 RESEARCH DATA
FIGURE 2 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
FIGURE 3 EPIGENETICS MARKET: BREAKDOWN OF PRIMARIES
2.2 MARKET SIZE ESTIMATION
FIGURE 4 MARKET SIZE ESTIMATION: BOTTOM-UP (SUPPLY SIDE): COLLECTIVE REVENUE OF EPIGENETICS IN THE MARKET
FIGURE 5 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS, 2021
FIGURE 6 AVERAGE MARKET SIZE ESTIMATION, 2021
2.3 GROWTH RATE ASSUMPTIONS/GROWTH FORECAST
FIGURE 7 EPIGENETICS MARKET: CAGR PROJECTIONS, 2022–2027
FIGURE 8 EPIGENETICS MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, CHALLENGES, AND OPPORTUNITIES
FIGURE 9 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 10 DATA TRIANGULATION METHODOLOGY
2.5 INSIGHTS FROM PRIMARIES
FIGURE 11 MARKET VALIDATION FROM PRIMARY EXPERTS
2.6 RESEARCH ASSUMPTIONS
2.6.1 COVID-19-SPECIFIC ASSUMPTIONS
2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY (Page No. – 49)
FIGURE 12 EPIGENETICS MARKET, BY PRODUCT & SERVICE, 2021 VS. 2027 (USD MILLION)
FIGURE 13 MARKET, BY METHOD, 2021 VS. 2027 (USD MILLION)
FIGURE 14 MARKET, BY TECHNIQUE, 2021 VS. 2027 (USD MILLION)
FIGURE 15 MARKET, BY APPLICATION, 2021 VS. 2027 (USD MILLION)
FIGURE 16 MARKET, BY END USER, 2021 VS. 2027 (USD MILLION)
FIGURE 17 GEOGRAPHICAL SNAPSHOT: EPIGENETICS MARKET

4 PREMIUM INSIGHTS (Page No. – 53)
4.1 EPIGENETICS MARKET OVERVIEW
FIGURE 18 GROWING USE OF EPIGENETIC ENZYMES IN DRUG DISCOVERY & DEVELOPMENT TO SUPPORT MARKET GROWTH
4.2 NORTH AMERICA: MARKET SHARE, BY PRODUCT & SERVICE AND COUNTRY (2021)
FIGURE 19 KITS & REAGENTS ACCOUNTED FOR THE LARGEST SHARE OF THE NORTH AMERICAN MARKET IN 2021
4.3 NORTH AMERICA: MARKET, BY METHOD, 2021 VS. 2027 (USD MILLION)
FIGURE 20 DNA METHYLATION TO DOMINATE THE NORTH AMERICAN MARKET TILL 2027

5 MARKET OVERVIEW (Page No. – 56)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 21 MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
TABLE 1 EPIGENETICS MARKET: IMPACT ANALYSIS
5.2.1 DRIVERS
5.2.1.1 Epigenetic enzymes gaining traction in drug discovery & development
TABLE 2 KEY EPIGENETIC ENZYMES FOR REPURPOSING DRUGS
5.2.1.2 Rising investments, funds, and grants for epigenetics research
5.2.1.3 Declining costs of genome sequencing
FIGURE 22 COST OF HUMAN WHOLE-GENOME SEQUENCING, 2001–2020
5.2.2 RESTRAINTS
5.2.2.1 Limited applications of epigenomic data in toxicology
5.2.3 OPPORTUNITIES
5.2.3.1 Use of epigenetics in non-oncology applications
5.2.4 CHALLENGES
5.2.4.1 Challenges associated with epigenetic editing
5.2.4.1.1 Off-target effect
5.2.4.1.2 Other challenges
5.3 SCENARIOS ARISING OUT OF UNCERTAINTIES AFFECTING MARKET GROWTH
FIGURE 23 IMPACT OF UNCERTAINTIES ON MARKET GROWTH
5.4 IMPACT OF COVID-19 ON THE EPIGENETICS MARKET
TABLE 3 EPIGENETIC IMPLICATIONS IN CORONAVIRUS INFECTION AND THERAPY
5.5 PORTER’S FIVE FORCES ANALYSIS
TABLE 4 EPIGENETICS MARKET: PORTER’S FIVE FORCES ANALYSIS
5.5.1 THREAT OF NEW ENTRANTS
5.5.2 THREAT OF SUBSTITUTES
5.5.3 BARGAINING POWER OF BUYERS
5.5.4 BARGAINING POWER OF SUPPLIERS
5.5.5 DEGREE OF COMPETITION
5.6 ECOSYSTEM ANALYSIS
FIGURE 24 ECOSYSTEM ANALYSIS: EPIGENETICS MARKET
5.7 VALUE CHAIN ANALYSIS
FIGURE 25 VALUE CHAIN ANALYSIS: EPIGENETICS MARKET
5.8 SUPPLY CHAIN ANALYSIS
TABLE 5 SUPPLY CHAIN ECOSYSTEM
5.9 REGULATORY ANALYSIS
TABLE 6 KEY REGULATORY AGENCIES

6 EPIGENETICS MARKET, BY PRODUCT & SERVICE (Page No. – 72)
6.1 INTRODUCTION
TABLE 7 MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
6.2 KITS & REAGENTS
TABLE 8 EPIGENETIC KITS & REAGENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 9 EPIGENETIC KITS & REAGENTS MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 10 NORTH AMERICA: EPIGENETIC KITS & REAGENTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 11 EUROPE: EPIGENETIC KITS & REAGENTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 12 ASIA PACIFIC: EPIGENETIC KITS & REAGENTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.2.1 ANTIBODIES
6.2.1.1 Increasing demand for recombinant antibodies for the detection of epigenetic targets propels the segment growth
TABLE 13 ANTIBODIES MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 14 NORTH AMERICA: ANTIBODIES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 15 EUROPE: ANTIBODIES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 16 ASIA PACIFIC: ANTIBODIES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.2.2 CHIP-SEQUENCING KITS & REAGENTS
6.2.2.1 Versatile applications of ChIP in epigenetic regulatory systems contribute to the segment’s dominant share
TABLE 17 CHIP-SEQ KITS & REAGENTS MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 18 NORTH AMERICA: CHIP-SEQ KITS & REAGENTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 19 EUROPE: CHIP-SEQ KITS & REAGENTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 20 ASIA PACIFIC: CHIP-SEQ KITS & REAGENTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.2.3 BISULFITE CONVERSION KITS & REAGENTS
6.2.3.1 Effectiveness of bisulfite conversion in gene-specific and genome-wide analyses to drive the demand for kits & reagents
TABLE 21 BISULFITE CONVERSION KITS & REAGENTS MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 22 NORTH AMERICA: BISULFITE CONVERSION KITS & REAGENTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 23 EUROPE: BISULFITE CONVERSION KITS & REAGENTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 24 ASIA PACIFIC: BISULFITE CONVERSION KITS & REAGENTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.2.4 WHOLE-GENOME AMPLIFICATION KITS & REAGENTS
6.2.4.1 Whole-genome amplification maintains the relative proportions of genes present in the original pool, increasing its preference among researchers
TABLE 25 WHOLE-GENOME AMPLIFICATION KITS & REAGENTS MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 26 NORTH AMERICA: WHOLE-GENOME AMPLIFICATION KITS & REAGENTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 27 EUROPE: WHOLE-GENOME AMPLIFICATION KITS & REAGENTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 28 ASIA PACIFIC: WHOLE-GENOME AMPLIFICATION KITS & REAGENTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.2.5 5-HMC & 5-MC ANALYSIS KITS & REAGENTS
6.2.5.1 Introduction of unique kits drives market growth
TABLE 29 5-HMC & 5-MC ANALYSIS KITS & REAGENTS MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 30 NORTH AMERICA: 5-HMC & 5-MC ANALYSIS KITS & REAGENTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 31 EUROPE: 5-HMC & 5-MC ANALYSIS KITS & REAGENTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 32 ASIA PACIFIC: 5-HMC & 5-MC ANALYSIS KITS & REAGENTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.2.6 HISTONES
6.2.6.1 Importance of chromatin-associated proteins & histones in epigenetic research to drive the segment growth
TABLE 33 HISTONES MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 34 NORTH AMERICA: HISTONES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 35 EUROPE: HISTONES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 36 ASIA PACIFIC: HISTONES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.2.7 OTHER KITS & REAGENTS
TABLE 37 OTHER KITS & REAGENTS MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 38 NORTH AMERICA: OTHER KITS & REAGENTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 39 EUROPE: OTHER KITS & REAGENTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 40 ASIA PACIFIC: OTHER KITS & REAGENTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.3 ENZYMES
TABLE 41 EPIGENETIC ENZYMES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 42 EPIGENETIC ENZYMES MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 43 NORTH AMERICA: EPIGENETIC ENZYMES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 44 EUROPE: EPIGENETIC ENZYMES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 45 ASIA PACIFIC: EPIGENETIC ENZYMES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.3.1 DNA-MODIFYING ENZYMES
6.3.1.1 Growing applications of DNA methylation to contribute to the segment’s dominant share
TABLE 46 DNA-MODIFYING ENZYMES MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 47 NORTH AMERICA: DNA-MODIFYING ENZYMES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 48 EUROPE: DNA-MODIFYING ENZYMES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 49 ASIA PACIFIC: DNA-MODIFYING ENZYMES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.3.2 PROTEIN-MODIFYING ENZYMES
6.3.2.1 Increasing pipeline of epigenetics-based drugs targeting histone-modifying enzymes to drive the segment growth
TABLE 50 PROTEIN-MODIFYING ENZYMES MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 51 NORTH AMERICA: PROTEIN-MODIFYING ENZYMES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 52 EUROPE: PROTEIN-MODIFYING ENZYMES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 53 ASIA PACIFIC: PROTEIN-MODIFYING ENZYMES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.3.3 OTHER ENZYMES
TABLE 54 OTHER ENZYMES MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 55 NORTH AMERICA: OTHER ENZYMES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 56 EUROPE: OTHER ENZYMES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 57 ASIA PACIFIC: OTHER ENZYMES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.4 INSTRUMENTS & ACCESSORIES
6.4.1 WIDE USAGE OF NGS INSTRUMENTS AND SONICATORS TO CONTRIBUTE TO THE SEGMENT REVENUE
TABLE 58 EPIGENETIC INSTRUMENTS & ACCESSORIES MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 59 NORTH AMERICA: EPIGENETIC INSTRUMENTS & ACCESSORIES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 60 EUROPE: EPIGENETIC INSTRUMENTS & ACCESSORIES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 61 ASIA PACIFIC: EPIGENETIC INSTRUMENTS & ACCESSORIES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.5 SOFTWARE
6.5.1 DEVELOPMENT OF VIABLE SOFTWARE SOLUTIONS FOR DNA METHYLATION, CHROMATIN, AND RNA ANALYSIS TO PROPEL SEGMENT GROWTH
TABLE 62 EPIGENETIC SOFTWARE MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 63 NORTH AMERICA: EPIGENETIC SOFTWARE MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 64 EUROPE: EPIGENETIC SOFTWARE MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 65 ASIA PACIFIC: EPIGENETIC SOFTWARE MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.6 SERVICES
6.6.1 EXPANDING POOL OF PROVIDERS TO DRIVE THE SERVICES SEGMENT
TABLE 66 EPIGENETIC SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 67 NORTH AMERICA: EPIGENETIC SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 68 EUROPE: EPIGENETIC SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 69 ASIA PACIFIC: EPIGENETIC SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)

7 EPIGENETICS MARKET, BY METHOD (Page No. – 100)
    7.1 INTRODUCTION
TABLE 70 MARKET, BY METHOD, 2020–2027 (USD MILLION)
7.2 DNA METHYLATION
7.2.1 DNA METHYLATION TO DOMINATE THE METHODS MARKET TILL 2027
TABLE 71 MARKET FOR DNA METHYLATION, BY REGION, 2020–2027 (USD MILLION)
TABLE 72 NORTH AMERICA: MARKET FOR DNA METHYLATION, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 73 EUROPE: MARKET FOR DNA METHYLATION, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 74 ASIA PACIFIC: MARKET FOR DNA METHYLATION, BY COUNTRY, 2020–2027 (USD MILLION)
7.3 HISTONE MODIFICATIONS
7.3.1 TECHNOLOGICAL ADVANCEMENTS TO DRIVE SEGMENT GROWTH
TABLE 75 COMMON HISTONE MODIFICATIONS AND RESPECTIVE LOCATIONS
TABLE 76 EPIGENETICS MARKET FOR HISTONE MODIFICATIONS, BY REGION, 2020–2027 (USD MILLION)
TABLE 77 NORTH AMERICA: MARKET FOR HISTONE MODIFICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 78 EUROPE: MARKET FOR HISTONE MODIFICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 79 ASIA PACIFIC: MARKET FOR HISTONE MODIFICATIONS,  BY COUNTRY, 2020–2027 (USD MILLION)
7.4 OTHER METHODS
TABLE 80 EPIGENETICS MARKET FOR OTHER METHODS, BY REGION, 2020–2027 (USD MILLION)
TABLE 81 NORTH AMERICA: MARKET FOR OTHER METHODS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 82 EUROPE: MARKET FOR OTHER METHODS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 83 ASIA PACIFIC: MARKET FOR OTHER METHODS, BY COUNTRY, 2020–2027 (USD MILLION)

8 EPIGENETICS MARKET, BY TECHNIQUE (Page No. – 108)
8.1 INTRODUCTION
TABLE 84 MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION)
8.2 NGS
8.2.1 NGS OFFERS COMPREHENSIVE EPIGENETIC PROFILES, WHICH DRIVES ADOPTION
TABLE 85 EPIGENETICS MARKET FOR NGS, BY REGION, 2020–2027 (USD MILLION)
TABLE 86 NORTH AMERICA: MARKET FOR NGS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 87 EUROPE: MARKET FOR NGS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 88 ASIA PACIFIC: MARKET FOR NGS, BY COUNTRY, 2020–2027 (USD MILLION)
8.3 PCR & QPCR
8.3.1 RISING NUMBER OF PCR-BASED EPIGENETICS SERVICE PROVIDERS TO PROPEL THE SEGMENT GROWTH
TABLE 89 EPIGENETICS MARKET FOR PCR & QPCR, BY REGION, 2020–2027 (USD MILLION)
TABLE 90 NORTH AMERICA: MARKET FOR PCR & QPCR, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 91 EUROPE: MARKET FOR PCR & QPCR, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 92 ASIA PACIFIC: MARKET FOR PCR & QPCR, BY COUNTRY, 2020–2027 (USD MILLION)
8.4 MASS SPECTROMETRY
8.4.1 GROWING DEMAND FOR MASS SPECTROMETRY IN HISTONE EPIGENETICS STUDIES TO DRIVE THE SEGMENT GROWTH
TABLE 93 EPIGENETICS MARKET FOR MASS SPECTROMETRY, BY REGION, 2020–2027 (USD MILLION)
TABLE 94 NORTH AMERICA: MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 95 EUROPE: MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 96 ASIA PACIFIC: MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2020–2027 (USD MILLION)
8.5 SONICATION
8.5.1 ADVENT OF IMPROVED HIGH-THROUGHPUT SONICATION TO PROPEL ITS ADOPTION IN EPIGENETICS STUDIES
TABLE 97 EPIGENETICS MARKET FOR SONICATION, BY REGION, 2020–2027 (USD MILLION)
TABLE 98 NORTH AMERICA: MARKET FOR SONICATION, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 99 EUROPE: MARKET FOR SONICATION, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 100 ASIA PACIFIC: MARKET FOR SONICATION, BY COUNTRY, 2020–2027 (USD MILLION)
8.6 OTHER TECHNIQUES
TABLE 101 EPIGENETICS MARKET FOR OTHER TECHNIQUES, BY REGION, 2020–2027 (USD MILLION)
TABLE 102 NORTH AMERICA: MARKET FOR OTHER TECHNIQUES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 103 EUROPE: MARKET FOR OTHER TECHNIQUES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 104 ASIA PACIFIC: MARKET FOR OTHER TECHNIQUES, BY COUNTRY, 2020–2027 (USD MILLION)

9 EPIGENETICS MARKET, BY APPLICATION (Page No. – 119)
9.1 INTRODUCTION
TABLE 105 MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
9.2 ONCOLOGY
9.2.1 ONCOLOGY TO HOLD LARGEST SHARE OF THE APPLICATIONS SEGMENT TILL 2027
TABLE 106 EPIGENOME-TARGETING CANCER DRUGS APPROVED OR IN CLINICAL TRIALS
TABLE 107 MARKET FOR ONCOLOGY, BY REGION, 2020–2027 (USD MILLION)
TABLE 108 NORTH AMERICA: MARKET FOR ONCOLOGY, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 109 EUROPE: MARKET FOR ONCOLOGY, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 110 ASIA PACIFIC: MARKET FOR ONCOLOGY, BY COUNTRY, 2020–2027 (USD MILLION)
9.3 METABOLIC DISEASES
9.3.1 EMERGING ROLE OF DNA METHYLATION IN DIABETES MANAGEMENT TO DRIVE THE SEGMENT GROWTH
TABLE 111 EPIGENETICS MARKET FOR METABOLIC DISEASES, BY REGION, 2020–2027 (USD MILLION)
TABLE 112 NORTH AMERICA: EPIGENETICS MARKET FOR METABOLIC DISEASES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 113 EUROPE: EPIGENETICS MARKET FOR METABOLIC DISEASES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 114 ASIA PACIFIC: EPIGENETICS MARKET FOR METABOLIC DISEASES, BY COUNTRY, 2020–2027 (USD MILLION)
9.4 IMMUNOLOGY
9.4.1 RISING DEMAND FOR EPIGENETICS PRODUCTS IN TUMOR AND TRANSPLANTATION IMMUNOLOGY TO DRIVE SEGMENT’S GROWTH
TABLE 115 EPIGENETICS MARKET FOR IMMUNOLOGY, BY REGION, 2020–2027 (USD MILLION)
TABLE 116 NORTH AMERICA: EPIGENETICS MARKET FOR IMMUNOLOGY, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 117 EUROPE: EPIGENETICS MARKET FOR IMMUNOLOGY, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 118 ASIA PACIFIC: EPIGENETICS MARKET FOR IMMUNOLOGY, BY COUNTRY, 2020–2027 (USD MILLION)
9.5 DEVELOPMENTAL BIOLOGY
9.5.1 GROWING R&D IN DEVELOPMENTAL BIOLOGY TO PROPEL THE SEGMENT’S GROWTH
TABLE 119 EPIGENETICS MARKET FOR DEVELOPMENTAL BIOLOGY, BY REGION, 2020–2027 (USD MILLION)
TABLE 120 NORTH AMERICA: EPIGENETICS MARKET FOR DEVELOPMENTAL BIOLOGY, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 121 EUROPE: EPIGENETICS MARKET FOR DEVELOPMENTAL BIOLOGY, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 122 ASIA PACIFIC: EPIGENETICS MARKET FOR DEVELOPMENTAL BIOLOGY, BY COUNTRY, 2020–2027 (USD MILLION)
9.6 CARDIOVASCULAR DISEASES
9.6.1 EMERGING ROLE OF EPIGENETICS IN UNDERSTANDING THE ETIOLOGY OF CARDIOVASCULAR DISEASES TO PROPEL PRODUCT ADOPTION
TABLE 123 EPIGENETICS MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2020–2027 (USD MILLION)
TABLE 124 NORTH AMERICA: EPIGENETICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 125 EUROPE: EPIGENETICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 126 ASIA PACIFIC: EPIGENETICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2020–2027 (USD MILLION)
9.7 OTHER APPLICATIONS
TABLE 127 EPIGENETICS MARKET FOR OTHER APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
TABLE 128 NORTH AMERICA: EPIGENETICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 129 EUROPE: EPIGENETICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 130 ASIA PACIFIC: EPIGENETICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)

10 EPIGENETICS MARKET, BY END USER (Page No. – 133)
10.1 INTRODUCTION
TABLE 131 EPIGENETICS MARKET, BY END USER, 2020–2027 (USD MILLION)
10.2 ACADEMIC & RESEARCH INSTITUTES
10.2.1 HIGH SHARE ATTRIBUTED TO RISING COLLABORATIONS AMONG RESEARCH INSTITUTES AND DEMAND FOR CANCER EPIGENETICS
TABLE 132 EPIGENETICS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2020–2027 (USD MILLION)
TABLE 133 NORTH AMERICA: EPIGENETICS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 134 EUROPE: EPIGENETICS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 135 ASIA PACIFIC: EPIGENETICS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION)
10.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
10.3.1 HIGH NUMBER OF CLINICAL TRIALS FOR EPIGENETICS-BASED DRUGS TO DRIVE THE SEGMENT GROWTH
TABLE 136 EPIGENETICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2020–2027 (USD MILLION)
TABLE 137 NORTH AMERICA: EPIGENETICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 138 EUROPE: EPIGENETICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 139 ASIA PACIFIC: EPIGENETICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION)
10.4 HOSPITALS & CLINICS
10.4.1 RISING IMPORTANCE OF DNA METHYLATION MEASUREMENTS TO DRIVE SEGMENT GROWTH
TABLE 140 EPIGENETICS MARKET FOR HOSPITALS & CLINICS, BY REGION, 2020–2027 (USD MILLION)
TABLE 141 NORTH AMERICA: EPIGENETICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 142 EUROPE: EPIGENETICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 143 ASIA PACIFIC: EPIGENETICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2020–2027 (USD MILLION)

11 EPIGENETICS MARKET, BY REGION (Page No. – 141)
11.1 INTRODUCTION
TABLE 144 EPIGENETICS MARKET, BY REGION, 2020–2027 (USD MILLION)
11.2 NORTH AMERICA
FIGURE 26 NORTH AMERICA: EPIGENETICS MARKET SNAPSHOT
TABLE 145 NORTH AMERICA: EPIGENETICS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 146 NORTH AMERICA: EPIGENETICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 147 NORTH AMERICA: EPIGENETIC KITS & REAGENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 148 NORTH AMERICA: EPIGENETIC ENZYMES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 149 NORTH AMERICA: EPIGENETICS MARKET, BY METHOD, 2020–2027 (USD MILLION)
TABLE 150 NORTH AMERICA: EPIGENETICS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION)
TABLE 151 NORTH AMERICA: EPIGENETICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 152 NORTH AMERICA: EPIGENETICS MARKET, BY END USER, 2020–2027 (USD MILLION)
11.2.1 US
11.2.1.1 A strong network of well-established epigenetic product manufacturers is the key growth contributor
TABLE 153 US: EPIGENETICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 154 US: EPIGENETIC KITS & REAGENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 155 US: EPIGENETIC ENZYMES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 156 US: EPIGENETICS MARKET, BY METHOD, 2020–2027 (USD MILLION)
TABLE 157 US: EPIGENETICS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION)
TABLE 158 US: EPIGENETICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 159 US: EPIGENETICS MARKET, BY END USER, 2020–2027 (USD MILLION)
11.2.2 CANADA
11.2.2.1 Government initiatives to boost epigenetics research contribute to the market growth
TABLE 160 CANADA: EPIGENETICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 161 CANADA: EPIGENETIC KITS & REAGENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 162 CANADA: EPIGENETIC ENZYMES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 163 CANADA: EPIGENETICS MARKET, BY METHOD, 2020–2027 (USD MILLION)
TABLE 164 CANADA: EPIGENETICS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION)
TABLE 165 CANADA: EPIGENETICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 166 CANADA: EPIGENETICS MARKET, BY END USER, 2020–2027 (USD MILLION)
11.3 EUROPE
TABLE 167 EUROPE: EPIGENETICS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 168 EUROPE: EPIGENETICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 169 EUROPE: EPIGENETIC KITS & REAGENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 170 EUROPE: EPIGENETIC ENZYMES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 171 EUROPE: EPIGENETICS MARKET, BY METHOD, 2020–2027 (USD MILLION)
TABLE 172 EUROPE: EPIGENETICS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION)
TABLE 173 EUROPE: EPIGENETICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 174 EUROPE: EPIGENETICS MARKET, BY END USER, 2020–2027 (USD MILLION)
11.3.1 GERMANY
11.3.1.1 Significant investments in the NGS market space in Germany expected to boost the uptake of epigenetics products
TABLE 175 GERMANY: EPIGENETICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 176 GERMANY: EPIGENETIC KITS & REAGENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 177 GERMANY: EPIGENETIC ENZYMES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 178 GERMANY: EPIGENETICS MARKET, BY METHOD, 2020–2027 (USD MILLION)
TABLE 179 GERMANY: EPIGENETICS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION)
TABLE 180 GERMANY: EPIGENETICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 181 GERMANY: EPIGENETICS MARKET, BY END USER, 2020–2027 (USD MILLION)
11.3.2 UK
11.3.2.1 Rising acceptance of genome-based diagnostic techniques to drive the UK epigenetics market
TABLE 182 UK: EPIGENETICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 183 UK: EPIGENETIC KITS & REAGENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 184 UK: EPIGENETIC ENZYMES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 185 UK: EPIGENETICS MARKET, BY METHOD, 2020–2027 (USD MILLION)
TABLE 186 UK: EPIGENETICS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION)
TABLE 187 UK: EPIGENETICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 188 UK: EPIGENETICS MARKET, BY END USER, 2020–2027 (USD MILLION)
11.3.3 FRANCE
11.3.3.1 Growing demand for PCR technologies propelled by favorable government initiatives to boost the market growth
TABLE 189 FRANCE: EPIGENETICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 190 FRANCE: EPIGENETIC KITS & REAGENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 191 FRANCE: EPIGENETIC ENZYMES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 192 FRANCE: EPIGENETICS MARKET, BY METHOD, 2020–2027 (USD MILLION)
TABLE 193 FRANCE: EPIGENETICS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION)
TABLE 194 FRANCE: EPIGENETICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 195 FRANCE: EPIGENETICS MARKET, BY END USER, 2020–2027 (USD MILLION)
11.3.4 REST OF EUROPE
TABLE 196 REST OF EUROPE: EPIGENETICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 197 REST OF EUROPE: EPIGENETIC KITS & REAGENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 198 REST OF EUROPE: EPIGENETIC ENZYMES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 199 REST OF EUROPE: EPIGENETICS MARKET, BY METHOD, 2020–2027 (USD MILLION)
TABLE 200 REST OF EUROPE: EPIGENETICS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION)
TABLE 201 REST OF EUROPE: EPIGENETICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 202 REST OF EUROPE: EPIGENETICS MARKET, BY END USER, 2020–2027 (USD MILLION)
11.4 ASIA PACIFIC
FIGURE 27 ASIA PACIFIC: EPIGENETICS MARKET SNAPSHOT
TABLE 203 ASIA PACIFIC: EPIGENETICS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 204 ASIA PACIFIC: EPIGENETICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 205 ASIA PACIFIC: EPIGENETIC KITS & REAGENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 206 ASIA PACIFIC: EPIGENETIC ENZYMES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 207 ASIA PACIFIC: EPIGENETICS MARKET, BY METHOD, 2020–2027 (USD MILLION)
TABLE 208 ASIA PACIFIC: EPIGENETICS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION)
TABLE 209 ASIA PACIFIC: EPIGENETICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 210 ASIA PACIFIC: EPIGENETICS MARKET, BY END USER, 2020–2027 (USD MILLION)
11.4.1 JAPAN
11.4.1.1 Research-academia collaborations have driven awareness of epigenetics in the country
TABLE 211 JAPAN: EPIGENETICS MARKET, BY PRODUCT & SERVICE,  2020–2027 (USD MILLION)
TABLE 212 JAPAN: EPIGENETIC KITS & REAGENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 213 JAPAN: EPIGENETIC ENZYMES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 214 JAPAN: EPIGENETICS MARKET, BY METHOD, 2020–2027 (USD MILLION)
TABLE 215 JAPAN: EPIGENETICS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION)
TABLE 216 JAPAN: EPIGENETICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 217 JAPAN: EPIGENETICS MARKET, BY END USER, 2020–2027 (USD MILLION)
11.4.2 CHINA
11.4.2.1 Increasing research on genomics and high demand for personalized medicine to propel the Chinese market
TABLE 218 CHINA: EPIGENETICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 219 CHINA: EPIGENETIC KITS & REAGENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 220 CHINA: EPIGENETIC ENZYMES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 221 CHINA: EPIGENETICS MARKET, BY METHOD, 2020–2027 (USD MILLION)
TABLE 222 CHINA: EPIGENETICS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION)
TABLE 223 CHINA: EPIGENETICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 224 CHINA: EPIGENETICS MARKET, BY END USER, 2020–2027 (USD MILLION)
11.4.3 INDIA
11.4.3.1 Activities to strengthen genomics research by expanding the base of biotechnology facilities to drive market growth
TABLE 225 INDIA: EPIGENETICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 226 INDIA: EPIGENETIC KITS & REAGENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 227 INDIA: EPIGENETIC ENZYMES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 228 INDIA: EPIGENETICS MARKET, BY METHOD, 2020–2027 (USD MILLION)
TABLE 229 INDIA: EPIGENETICS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION)
TABLE 230 INDIA: EPIGENETICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 231 INDIA: EPIGENETICS MARKET, BY END USER, 2020–2027 (USD MILLION)
11.4.4 REST OF ASIA PACIFIC
TABLE 232 REST OF ASIA PACIFIC: EPIGENETICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 233 REST OF ASIA PACIFIC: EPIGENETIC KITS & REAGENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 234 REST OF ASIA PACIFIC: EPIGENETIC ENZYMES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 235 REST OF ASIA PACIFIC: EPIGENETICS MARKET, BY METHOD, 2020–2027 (USD MILLION)
TABLE 236 REST OF ASIA PACIFIC: EPIGENETICS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION)
TABLE 237 REST OF ASIA PACIFIC: EPIGENETICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 238 REST OF ASIA PACIFIC: EPIGENETICS MARKET, BY END USER, 2020–2027 (USD MILLION)
11.5 LATIN AMERICA
11.5.1 ADVANCEMENTS IN EPIGENETIC ANALYSIS AND CHARACTERIZATION TO BOOST THE UPTAKE OF MARKET PRODUCTS
TABLE 239 LATIN AMERICA: EPIGENETICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 240 LATIN AMERICA: EPIGENETIC KITS & REAGENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 241 LATIN AMERICA: EPIGENETIC ENZYMES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 242 LATIN AMERICA: EPIGENETICS MARKET, BY METHOD, 2020–2027 (USD MILLION)
TABLE 243 LATIN AMERICA: EPIGENETICS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION)
TABLE 244 LATIN AMERICA: EPIGENETICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 245 LATIN AMERICA: EPIGENETICS MARKET, BY END USER, 2020–2027 (USD MILLION)
11.6 MIDDLE EAST & AFRICA
11.6.1 RISING FUNDING AND PARTNERSHIPS IN RESEARCH TO BOOST MARKET GROWTH IN THE MIDDLE EAST & AFRICA
TABLE 246 MIDDLE EAST & AFRICA: EPIGENETICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 247 MIDDLE EAST & AFRICA: EPIGENETIC KITS & REAGENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 248 MIDDLE EAST & AFRICA: EPIGENETIC ENZYMES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 249 MIDDLE EAST & AFRICA: EPIGENETICS MARKET, BY METHOD, 2020–2027 (USD MILLION)
TABLE 250 MIDDLE EAST & AFRICA: EPIGENETICS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION)
TABLE 251 MIDDLE EAST & AFRICA: EPIGENETICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 252 MIDDLE EAST & AFRICA: EPIGENETICS MARKET, BY END USER, 2020–2027 (USD MILLION)

12 COMPETITIVE LANDSCAPE (Page No. – 189)
12.1 INTRODUCTION
12.2 RIGHT-TO-WIN APPROACHES ADOPTED BY KEY PLAYERS
FIGURE 28 EPIGENETICS MARKET: STRATEGIES ADOPTED
12.3 MARKET SHARE ANALYSIS
FIGURE 29 EPIGENETICS MARKET: MARKET SHARE ANALYSIS OF TOP 5 PLAYERS (2021)
12.4 REVENUE SHARE ANALYSIS (TOP 5 MARKET PLAYERS)
FIGURE 30 REVENUE ANALYSIS FOR KEY COMPANIES OVER THE PAST 2-3 YEARS
12.5 COMPANY EVALUATION QUADRANT (KEY MARKET PLAYERS)
FIGURE 31 EPIGENETICS MARKET: COMPANY EVALUATION MATRIX, 2021
12.5.1 STARS
12.5.2 EMERGING LEADERS
12.5.3 PERVASIVE PLAYERS
12.5.4 PARTICIPANTS
12.5.5 COMPETITIVE BENCHMARKING—STARTUPS/SMES
TABLE 253 EPIGENETICS MARKET: DETAILED LIST OF KEY STARTUPS/SMES
TABLE 254 EPIGENETICS MARKET: COMPETITIVE BENCHMARKING OF KEY PLAYERS [STARTUPS/SMES]
12.6 COMPETITIVE SCENARIO AND TRENDS
12.6.1 PRODUCT LAUNCHES
TABLE 255 EPIGENETICS MARKET: PRODUCT LAUNCHES
12.6.2 DEALS
TABLE 256 EPIGENETICS MARKET: ACQUISITIONS

13 COMPANY PROFILES (Page No. – 197)
13.1 KEY COMPANIES
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
13.1.1 THERMO FISHER SCIENTIFIC INC.
TABLE 257 THERMO FISHER SCIENTIFIC: BUSINESS OVERVIEW
FIGURE 32 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT
13.1.2 ILLUMINA, INC.
TABLE 258 ILLUMINA, INC.: BUSINESS OVERVIEW
FIGURE 33 ILLUMINA, INC.: COMPANY SNAPSHOT
13.1.3 PACIFIC BIOSCIENCES
TABLE 259 PACBIO: BUSINESS OVERVIEW
FIGURE 34 PACBIO: COMPANY SNAPSHOT
13.1.4 ABCAM PLC.
TABLE 260 ABCAM PLC.: BUSINESS OVERVIEW
FIGURE 35 ABCAM PLC: COMPANY SNAPSHOT
13.1.5 MERCK KGAA
TABLE 261 MERCK KGAA: BUSINESS OVERVIEW
FIGURE 36 MERCK KGAA: COMPANY SNAPSHOT
13.1.6 BIO-RAD LABORATORIES, INC.
TABLE 262 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW
FIGURE 37 BIO-RAD LABORATORIES: COMPANY SNAPSHOT
13.1.7 ACTIVE MOTIF
TABLE 263 ACTIVE MOTIF: BUSINESS OVERVIEW
13.1.8 NEW ENGLAND BIOLABS
TABLE 264 NEW ENGLAND BIOLABS: BUSINESS OVERVIEW
13.1.9 QIAGEN
TABLE 265 QIAGEN: BUSINESS OVERVIEW
FIGURE 38 QIAGEN: COMPANY SNAPSHOT
13.1.10 ZYMO RESEARCH CORPORATION
TABLE 266 ZYMO RESEARCH CORPORATION: BUSINESS OVERVIEW
13.1.11 PERKINELMER INC.
TABLE 267 PERKINELMER INC.: BUSINESS OVERVIEW
13.1.12 DIAGENODE
TABLE 268 DIAGENODE: BUSINESS OVERVIEW
13.1.13 F. HOFFMANN-LA ROCHE LTD
TABLE 269 F. HOFFMANN-LA ROCHE LTD: BUSINESS OVERVIEW
FIGURE 39 F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT
13.1.14 PROMEGA CORPORATION
TABLE 270 PROMEGA CORPORATION: BUSINESS OVERVIEW
13.2 OTHER PLAYERS
13.2.1 EPIGENTEK GROUP INC.
13.2.2 EPICYPHER
13.2.3 EVERON LIFE SCIENCES
13.2.4 FIOS GENOMICS
13.2.5 GENOMESCAN
13.2.6 CREATIVE BIOGENE

*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.

14 APPENDIX (Page No. – 240)
14.1 DISCUSSION GUIDE
14.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
14.3 AVAILABLE CUSTOMIZATIONS
14.4 RELATED REPORTS
14.5 AUTHOR DETAILS


    • 리포트 제목은 자동으로 입력됩니다.
    • *항목은 필수항목입니다.

    의뢰분류*

    성함*

    회사명*

    부서명

    이메일*

    전화번호

    저희 사이트를 알게 된 경로를 가르쳐 주세요.

    문의 내용*

     

    ※개인정보보호정책은여기에서 확인 가능합니다。

    Email 문의도 받고 있습니다.
    아래 주소이며 죄송하지만 "(at)"을 "@"로 바꾸어 보내주시길 부탁드립니다.
    mooneui(at)chosareport-korea.com